कंपनी लोड हो रही है
Moderna, Inc.
MRNA · Nasdaq · ·
$223.22-3.5%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 6 नवंबर 2026 को दाखिल 10-Q से
पिछला प्रदर्शन
- 1W
- -12.2%
- 1M
- -5.6%
MRNA · Nasdaq · ·
$223.22-3.5%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 6 नवंबर 2026 को दाखिल 10-Q से
Just reported
From Moderna's results release of 6 नवंबर 2026; its quarterly report has since been filed.
Actual
$1.31B
+29% y/y
Guided
—
No guide given
Actual
$0.38
Guided
—
No guide given
Actual
$130M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now Aआमदनी के हिस्से year ended 2025-12-31 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.
mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.
Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.
Moderna, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
Moderna sells COVID-19 vaccines mainly to wholesalers, distributors and governments, plus vaccines for respiratory syncytial virus (RSV) and influenza.
Grade C-
भाव के नीचे की पट्टी हर तारीख की ग्रेड दिखाती है, जो सिर्फ़ उस समय तक सार्वजनिक दस्तावेज़ों से बनी है।
Moderna, Inc. के ग्रेड इतिहास की 32 तिमाहियों में से 2 दिखाई जा रही हैं। बाकी 30 मार्च 2019 तक जाती हैं।
